Assistant Professor of Neurology
Harvard Medical School
Clinical Director, Partners Multiple Sclerosis Center
Dr. Stankiewicz discloses the following:
Consultant: EMD-Serono, Sanofi-Genzyme, Genentech
Advisory Board Membership: Novartis, Celgene, Biogen-Idec
Assistant Professor, Division of Neurology
St. Michael’s Hospital, University of Toronto
Assistant Professor, Department of Neurology
Johns Hopkins School of Medicine
Staff Neurologist, St. Michael’s Hospital
Scientist, Keenan Research Centre of the
Li Ka Shing Knowledge Institute
Dr. Oh discloses the following:
Grants/research support: Roche, Biogen-Idec, Sanofi-Genzyme
Consultant: Roche, Biogen-Idec, Sanofi-Genzyme, Celgene, EMD-Serono
Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
In this educational activity, the faculty reports that their presentation will not contain reference to investigational and/or off-label uses.
Neurology clinicians (including physicians, NPs, PAs) and others who encounter patients with MS.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and MCM Education. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 30, 2019, through August 30, 2020:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 80% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Concise CCO activity on selecting second-generation antipsychotics for treatment augmentation in patients with MDD and managing adverse events
Free slides from CCO and Rakesh Jain, MD, MPH: Expert insights on efficacy, role of antipsychotics in MDD, mitigating and manage adverse events
Free slides from CCO and Christoph U. Correll, MD: Expert insights on comorbidities in treatment augmentation for MDD
Expert commentary on prevention and emerging treatment strategies for the COVID-19 pandemic from CCO
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.